AAPL299.63+1.62 (+0.54%) ▲|ABBV231.64+15.15 (+7.00%) ▲|ABT88.28-0.13 (-0.15%) ▼|ACN121.06-6.92 (-5.41%) ▼|ADBE192.74-2.43 (-1.24%) ▼|AMAT623.55+6.44 (+1.04%) ▲|AMD542.39+5.02 (+0.93%) ▲|AMGN344.78+7.18 (+2.13%) ▲|AMT178.34+2.29 (+1.30%) ▲|AMZN232.30-12.09 (-4.95%) ▼|AVGO396.37-14.98 (-3.64%) ▼|AXP337.59-0.41 (-0.12%) ▼|BA221.70-1.02 (-0.46%) ▼|BAC57.41+1.21 (+2.14%) ▲|BKNG168.87-2.91 (-1.69%) ▼|BLK1,054.13+4.04 (+0.38%) ▲|BMY54.58+0.58 (+1.06%) ▲|BNY145.88+2.25 (+1.56%) ▲|BRK-B487.81-1.65 (-0.34%) ▼|C145.61+2.55 (+1.78%) ▲|CAT1,021.44+35.62 (+3.61%) ▲|CL90.18+0.70 (+0.78%) ▲|CMCSA22.36-0.08 (-0.33%) ▼|COF201.66+0.13 (+0.06%) ▲|COP109.69+1.95 (+1.81%) ▲|COST950.50-0.96 (-0.10%) ▼|CRM147.76-4.02 (-2.65%) ▼|CSCO121.32+1.78 (+1.48%) ▲|CVS102.72+4.40 (+4.48%) ▲|CVX175.12+1.49 (+0.86%) ▲|DE601.99+12.75 (+2.16%) ▲|DHR178.90+1.73 (+0.98%) ▲|DIS101.63-2.26 (-2.18%) ▼|DUK124.52+0.66 (+0.53%) ▲|EMR150.83+0.17 (+0.11%) ▲|FDX330.97+5.99 (+1.84%) ▲|GD345.25-4.76 (-1.36%) ▼|GE356.88-0.76 (-0.21%) ▼|GEV1,127.59+17.86 (+1.61%) ▲|GILD124.36+0.60 (+0.48%) ▲|GM82.33+3.04 (+3.83%) ▲|GOOG345.10-22.37 (-6.09%) ▼|GOOGL345.74-22.29 (-6.06%) ▼|GS1,099.80+3.24 (+0.30%) ▲|HD328.45-5.83 (-1.74%) ▼|HON229.22+0.21 (+0.09%) ▲|IBM245.24-3.86 (-1.55%) ▼|INTC139.65+5.66 (+4.22%) ▲|INTU255.40-11.60 (-4.34%) ▼|ISRG402.56-4.23 (-1.04%) ▼|JNJ231.01+2.62 (+1.15%) ▲|JPM331.05+5.83 (+1.79%) ▲|KO79.87+0.48 (+0.60%) ▲|LIN516.61+4.46 (+0.87%) ▲|LLY1,112.04+13.47 (+1.23%) ▲|LMT494.24-16.71 (-3.27%) ▼|LOW215.14-7.06 (-3.18%) ▼|LRCX396.71+7.67 (+1.97%) ▲|MA485.69-4.10 (-0.84%) ▼|MCD272.48-6.14 (-2.20%) ▼|MDLZ60.23+0.11 (+0.17%) ▲|MDT79.55+0.21 (+0.26%) ▲|META562.18-15.04 (-2.61%) ▼|MMM162.72+2.12 (+1.32%) ▲|MO69.85+0.73 (+1.06%) ▲|MRK115.19+1.32 (+1.15%) ▲|MS227.57+4.40 (+1.97%) ▲|MSFT368.75-10.65 (-2.81%) ▼|MU1,191.05+57.06 (+5.03%) ▲|NEE86.96+0.21 (+0.24%) ▲|NFLX72.25-5.13 (-6.63%) ▼|NKE43.47-1.74 (-3.84%) ▼|NOW92.08-2.96 (-3.11%) ▼|NVDA209.08-1.61 (-0.76%) ▼|ORCL174.79-9.51 (-5.16%) ▼|PEP141.72-0.30 (-0.21%) ▼|PFE25.11-0.11 (-0.42%) ▼|PG149.26-1.12 (-0.74%) ▼|PLTR120.79-7.68 (-5.98%) ▼|PM174.96-3.45 (-1.93%) ▼|QCOM228.96+2.85 (+1.26%) ▲|RTX181.87-3.73 (-2.01%) ▼|SBUX100.82+0.17 (+0.17%) ▲|SCHW91.90+0.20 (+0.22%) ▲|SO94.07+0.98 (+1.05%) ▲|SPG213.77+2.44 (+1.15%) ▲|T22.22+0.21 (+0.93%) ▲|TMO463.95-0.67 (-0.14%) ▼|TMUS181.32-0.36 (-0.20%) ▼|TSLA407.24+6.75 (+1.69%) ▲|TXN329.37+6.51 (+2.02%) ▲|UBER72.13+0.49 (+0.68%) ▲|UNH408.67+7.71 (+1.92%) ▲|UNP262.51+5.63 (+2.19%) ▲|UPS108.49+3.63 (+3.46%) ▲|USB58.80+0.66 (+1.14%) ▲|V329.09+1.85 (+0.56%) ▲|VZ45.40+0.03 (+0.06%) ▲|WFC83.76+1.56 (+1.90%) ▲|WMT117.46+0.28 (+0.24%) ▲|XOM138.80+0.99 (+0.72%) ▲|AAPL299.63+1.62 (+0.54%) ▲|ABBV231.64+15.15 (+7.00%) ▲|ABT88.28-0.13 (-0.15%) ▼|ACN121.06-6.92 (-5.41%) ▼|ADBE192.74-2.43 (-1.24%) ▼|AMAT623.55+6.44 (+1.04%) ▲|AMD542.39+5.02 (+0.93%) ▲|AMGN344.78+7.18 (+2.13%) ▲|AMT178.34+2.29 (+1.30%) ▲|AMZN232.30-12.09 (-4.95%) ▼|AVGO396.37-14.98 (-3.64%) ▼|AXP337.59-0.41 (-0.12%) ▼|BA221.70-1.02 (-0.46%) ▼|BAC57.41+1.21 (+2.14%) ▲|BKNG168.87-2.91 (-1.69%) ▼|BLK1,054.13+4.04 (+0.38%) ▲|BMY54.58+0.58 (+1.06%) ▲|BNY145.88+2.25 (+1.56%) ▲|BRK-B487.81-1.65 (-0.34%) ▼|C145.61+2.55 (+1.78%) ▲|CAT1,021.44+35.62 (+3.61%) ▲|CL90.18+0.70 (+0.78%) ▲|CMCSA22.36-0.08 (-0.33%) ▼|COF201.66+0.13 (+0.06%) ▲|COP109.69+1.95 (+1.81%) ▲|COST950.50-0.96 (-0.10%) ▼|CRM147.76-4.02 (-2.65%) ▼|CSCO121.32+1.78 (+1.48%) ▲|CVS102.72+4.40 (+4.48%) ▲|CVX175.12+1.49 (+0.86%) ▲|DE601.99+12.75 (+2.16%) ▲|DHR178.90+1.73 (+0.98%) ▲|DIS101.63-2.26 (-2.18%) ▼|DUK124.52+0.66 (+0.53%) ▲|EMR150.83+0.17 (+0.11%) ▲|FDX330.97+5.99 (+1.84%) ▲|GD345.25-4.76 (-1.36%) ▼|GE356.88-0.76 (-0.21%) ▼|GEV1,127.59+17.86 (+1.61%) ▲|GILD124.36+0.60 (+0.48%) ▲|GM82.33+3.04 (+3.83%) ▲|GOOG345.10-22.37 (-6.09%) ▼|GOOGL345.74-22.29 (-6.06%) ▼|GS1,099.80+3.24 (+0.30%) ▲|HD328.45-5.83 (-1.74%) ▼|HON229.22+0.21 (+0.09%) ▲|IBM245.24-3.86 (-1.55%) ▼|INTC139.65+5.66 (+4.22%) ▲|INTU255.40-11.60 (-4.34%) ▼|ISRG402.56-4.23 (-1.04%) ▼|JNJ231.01+2.62 (+1.15%) ▲|JPM331.05+5.83 (+1.79%) ▲|KO79.87+0.48 (+0.60%) ▲|LIN516.61+4.46 (+0.87%) ▲|LLY1,112.04+13.47 (+1.23%) ▲|LMT494.24-16.71 (-3.27%) ▼|LOW215.14-7.06 (-3.18%) ▼|LRCX396.71+7.67 (+1.97%) ▲|MA485.69-4.10 (-0.84%) ▼|MCD272.48-6.14 (-2.20%) ▼|MDLZ60.23+0.11 (+0.17%) ▲|MDT79.55+0.21 (+0.26%) ▲|META562.18-15.04 (-2.61%) ▼|MMM162.72+2.12 (+1.32%) ▲|MO69.85+0.73 (+1.06%) ▲|MRK115.19+1.32 (+1.15%) ▲|MS227.57+4.40 (+1.97%) ▲|MSFT368.75-10.65 (-2.81%) ▼|MU1,191.05+57.06 (+5.03%) ▲|NEE86.96+0.21 (+0.24%) ▲|NFLX72.25-5.13 (-6.63%) ▼|NKE43.47-1.74 (-3.84%) ▼|NOW92.08-2.96 (-3.11%) ▼|NVDA209.08-1.61 (-0.76%) ▼|ORCL174.79-9.51 (-5.16%) ▼|PEP141.72-0.30 (-0.21%) ▼|PFE25.11-0.11 (-0.42%) ▼|PG149.26-1.12 (-0.74%) ▼|PLTR120.79-7.68 (-5.98%) ▼|PM174.96-3.45 (-1.93%) ▼|QCOM228.96+2.85 (+1.26%) ▲|RTX181.87-3.73 (-2.01%) ▼|SBUX100.82+0.17 (+0.17%) ▲|SCHW91.90+0.20 (+0.22%) ▲|SO94.07+0.98 (+1.05%) ▲|SPG213.77+2.44 (+1.15%) ▲|T22.22+0.21 (+0.93%) ▲|TMO463.95-0.67 (-0.14%) ▼|TMUS181.32-0.36 (-0.20%) ▼|TSLA407.24+6.75 (+1.69%) ▲|TXN329.37+6.51 (+2.02%) ▲|UBER72.13+0.49 (+0.68%) ▲|UNH408.67+7.71 (+1.92%) ▲|UNP262.51+5.63 (+2.19%) ▲|UPS108.49+3.63 (+3.46%) ▲|USB58.80+0.66 (+1.14%) ▲|V329.09+1.85 (+0.56%) ▲|VZ45.40+0.03 (+0.06%) ▲|WFC83.76+1.56 (+1.90%) ▲|WMT117.46+0.28 (+0.24%) ▲|XOM138.80+0.99 (+0.72%) ▲|
22.6 C
New York
Monday, June 22, 2026

Tag: congress

newssourceFORcompanyinformationcontent1marketreleases

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib 
New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib

Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025

HAMPTON, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab in chronic spontaneous urticaria (CSU), an immune-related condition driven by mast cell activation. Barzolvolimab specifically targets mast cells by binding the receptor tyrosine kinase KIT with high specificity and potently inhibiting its activity, which is required for mast cell function and survival.

Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses

-- Breadth of presentations, including one oral and two flash talks, showcase Blueprint Medicines' leadership role in advancing care for patients with systemic mastocytosis...

DBV Technologies to Participate in Upcoming EAACI Congress 2025

Châtillon, France, June 12, 2025

Galapagos to Present New ATALANTA-1 CAR-T Data at EHA 2025, Highlighting Low Toxicity and Rapid, Decentralized Delivery of Fresh, Early-Memory-Enriched GLPG5101 in R/R NHL

Data reported from the ongoing ATALANTA-1 Phase 1/2 study in a heavily pretreated relapsed refractory non-Hodgkin’s Lymphoma (R/R NHL) patient population demonstrate low rates of high-grade toxicities

ATA Applauds President Trump for Revoking California’s Destructive EV Mandates

WASHINGTON, June 12, 2025 /PRNewswire/ -- The American Trucking Associations today thanked President Trump for revoking California's ruinous electric vehicle mandates and was honored...

Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025

– Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients –

Specialised Therapeutics Expands Partnership with Incyte to Include Two Additional Therapies for Hard-to-Treat Conditions

SINGAPORE, June 12, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce the expansion of its existing supply and distribution agreement...

As Public Cancer Funding Wavers, Oncology’s Brightest Breakthroughs Are Coming From Industry

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /CNW/ -- Equity Insider News Commentary – The 2025 ASCO...

Aemetis CEO Meets with White House, Congress, and Agencies Regarding Support for Domestic Energy and Rural Communities in Budget Bill

Aemetis CEO Meets with White House, Congress and Agencies Regarding Support for Domestic Energy and Rural Communities in Budget Bill

Armored Vehicles Market worth $60.7 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 12, 2025 /PRNewswire/ -- The armored vehicle market is estimated at USD 51.6 billion in 2025 and is projected to reach...

Industrial Rubber Market worth $14.90 billion by 2030 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 12, 2025 /PRNewswire/ -- The report "Industrial Rubber Market by Application (Automotive, Building & Construction, Industrial Manufacturing, Polymer Modification, Wire &...

Dizal Showcases Two First-in-Class Therapies in Hematologic Malignancies at EHA and ICML 2025

Golidocitinib demonstrated promising efficacy in maintaining and enhancing tumor response in peripheral T-cell lymphoma (PTCL) post first-line therapy with a 24-month disease-free survival (DFS)...

Industrial Enzymes Market worth $12.01 billion by 2030- Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 12, 2025 /PRNewswire/ -- The industrial enzymes market is estimated at USD 8.42 billion in 2025 and is projected to...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCongress

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers